Azithromycin for the treatment and control of trachoma

REFERENCES

• WORLD HEALTH ORGANISATION: Global initiative for the elimination of avoidable blindness. Geneva: WHO (1997).
   Google Scholar
• TREHARNE JD: The microbial epidemiology of trachoma. Int. Ophthalmal. (1988) 12:25–29.
   PubMedGoogle Scholar
• DAWSON CR, JONES BR, TARIZZO ML: Guide to trachoma control. Geneva: WHO (1981).
   Google Scholar
• BAILEY R, DUONG T, CARPENTER R, WHITTLE H, MABEY D: The duration of human ocular Chlamydia trachomatis infection is age dependent. Epidemial. Infect. (1999) 123:479–486.
   PubMed Web of Science ®Google Scholar
• THYLEFORS B, NEGREL AD, PARARAJASEGARAM R, DADZIE KY: Global data on blindness. Bull. World Health Org. (1995) 73:115–121.
   PubMed Web of Science ®Google Scholar
• AL RIFAI KM: Trachoma through history. Int. Ophthalmal. (1988) 12:9–14.
   PubMedGoogle Scholar
• SCHACHTER J, DAWSON CR: The epidemiology of trachoma predicts more blindness in the future. Scam/. j Infect. Dis. Suppl (1990) 69:55–62.
   PubMedGoogle Scholar
• WORLD HEALTH ORGANISATION: Report of the first meeting of the WHO Alliance for the Global Elimination of Trachoma, Geneva, Switzerland (30 June - 1 July 1997).
   Google Scholar
• MALATY R, ZAKI S, SAID ME, VASTINE DW, DAWSON DW, SCHACHTER J: Extraocular infections in children in areas with endemic trachoma. Infect. Dis. (1981) 143:853.
   Google Scholar
• NEGREL AD: The winning hand to defeat trachoma. Rev Int. Trach. Pathol. Ocul. Trap. Subtrop. Sante Publique (1999):73–125.
   Google Scholar
• LODE H, BORNER K, KOEPPE E SCHABERG T: Azithromycin - review of key chemical, pharmacokinetic and microbiological features. _J. Antimicrob. Chemother. (1996) 37(Suppl. C):1–8.
   Google Scholar
• FIESE EF, STEFFEN SH: Comparison of the acid stability of azithromycin and erythromycin A. j Antimicrob. Chemother (1990) 25(Suppl. A):39–47.
   Google Scholar
• FOULDS G, SHEPARD RM, JOHNSON RB: The pharmacokinetics of azithromycin in human serum and tissues. j Antimicrob. Chemother (1990) 25(Suppl. A):73–82.
   Google Scholar
• SCHENTAG JJ, BALLOW CH: Tissue-directed pharmacokinetics. Am. j Med. (1991) 91:5S–11S.
   Google Scholar
• WILLIAMS JD: Spectrum of activity of azithromycin. Eur. j CBI]. Microbial Infect. Dis. (1991) 10:813–820.
   PubMed Web of Science ®Google Scholar
• SCIEUX C, BIANCHI A, CHAPPEY B, VASSIAS I, PEROL Y: In vitro activity of azithromycin against Chlamydia trachomatis. Antimicrob. Chemother (1990) 25(Suppl. A):7–10.
   Google Scholar
• SLANEY L, CHUBB H, RONALD A, BRUNHAM R: In vitro activity of azithromycin, erythromycin, ciprofloxacin and norfloxacin against Neisseria garrarrhoeae, Haemophilus ducreyi, and Chlamydia trachomatis. I Antimicrob. Chemother (1990) 25(Suppl. A):1–5.
   Google Scholar
• MARTIN DH, MROCZKOWSKI TF, DALU ZA et al.: A controlled trial of a single dose of azithromycin for the treatment of chlamydial urethritis and cervicitis. The Azithromycin for Chlamydial Infections Study Group. N Engl. j Med. (1992) 327:921–925.
   PubMed Web of Science ®Google Scholar
• TABBARA KF, AL KHARASHI SA, AL MANSOURI SM et al.: Ocular levels of azithromycin. Arch. °phthalate]. (1998) 116:1625–1628.
   Google Scholar
• KARCIOGLU ZA, EL YAZIGI A, JABAK MH, CHOUDHURY AH, AHMED WS: Pharmacokinetics of azithromycin in trachoma patients: serum and tear levels. Ophthalmology (1998) 105:658–661.
   PubMed Web of Science ®Google Scholar
• BAILEY RL, ARULLENDRAN E WHITTLE HC, MABEY DC: Randomised controlled trial of single-dose azithromycin in treatment of trachoma. Lancet (1993) 342:453-456. ••First trial of azithromycin for the treatment of trachoma.
   Google Scholar
• TABBARA KF, ABU-EL-ASRAR A, AL OMAR 0, CHOUDHURY AH, AL FAISAL Z: Single-dose azithromycin in the treatment of trachoma. A randomized, controlled study. Ophthalmology (1996) 103:842–846.
   PubMed Web of Science ®Google Scholar
• DAWSON CR, SCHACHTER J, SALLAM S, SHETA A, RUBINSTEIN RA, WASHTON H: A comparison of oral azithromycin with topical oxytetracyclinei polymyxin for the treatment of trachoma in children. CBI]. Infect. Dis. (1997) 24:363–368.
   PubMed Web of Science ®Google Scholar
• BOWMAN RJ, SILLAH A, DEHN C et al.: Operational comparison of single-dose azithromycin and topical tetracycline for trachoma. Invest. °phthalate]. Vis. ScL (2000) 41:4074-4079. •This comparison found azithromycin to be superior to tetracycline under operational conditions.
   Google Scholar
• DAWSON CR, MARX R, DAGHFOUS T, JUSTER R, SCHACHTER J: What clinical signs are critical in evaluating the intervention in trachoma? In: Chlarnydial Infections. Bowie WR (Ed.), Cambridge University Press, Cambridge, UK (1990):271–278.
   Google Scholar
• WEST S, MUNOZ B, BOBO L et al.: Non-ocular Chlamydia infection and risk of ocular re-infection after mass treatment in a trachoma hyperendemic area. Invest. °phthalate]. Vis. Li. (1993) 34:3194–3198.
   PubMed Web of Science ®Google Scholar
• WARD M, BAILEY R, LESLEY A, KAJBAF M, ROBERTSON J, MABEY D: Persisting in apparent chlamydial infection in a trachoma endemic community in The Gambia. Scam/. I Infect. Dis. Suppl (1990) 69:137–148.
   PubMedGoogle Scholar
• SCHACHTER J, WEST SK, MABEY D etal.: Azithromycin in control of trachoma. Lancet (1999) 354:630-635. •Mass treatment trial
   Google Scholar
• HOPKINS S: Clinical toleration and safetyof azithromycin. Am. J. Med. (1991) 91:40S–45S.
   Google Scholar
• WHITTY CJ, GLASGOW KW, SADIQ Si MABEY DC, BAILEY R: Impact of community-based mass treatment for trachoma with oral azithromycin on general morbidity in Gambian children. Pediatr. Infect. Dis. J (1999) 18:955–958.
   PubMedGoogle Scholar
• SADIQ ST, GLASGOW KW, DRAKELEY CJ et al.: Effects of azithromycin on malariometric indices in the Gambia. Lancet (1995) 346:881–882.
   PubMedGoogle Scholar
• WORLD HEALTH ORGANISATION: Future approaches to trachoma control - report of a global scientific meeting. (17–20 June 1996). WHOHPBL/96.56. (1996). Geneva: WHO.
   Google Scholar
• SOMANI J, BHULLAR V, WORKOWSKI K, FARSHY C, BLACK C: Multiple drug-resistant Chlamydia trachomatis associated with clinical treatment failure. j Infect. Dis. (2001) 181:1421–1427.
   Google Scholar
• LEACH AJ, SHELBY-JAMES TM, MAYO M eta].: A prospective study of the impact of community-based azithromycin treatment of trachoma on carriage and resistance of Streptococcus prieumarriae. Clirr. Infect. Dis. (1997) 24:356–362.
   Google Scholar
• MORITA JY, KAHN E, THOMPSON T et al.: Impact of azithromycin on oropharyngeal carriage of group A Streptococcus and nasopharyngeal carriage of macrolide-resistant Streptococcus prieumaniae. Pediatr. Infect. Dis. j (2000) 19:41–46.
   PubMed Web of Science ®Google Scholar
• PETERSON J, TREADWAY G: Impact of community-based azithromycin treatment of trachoma on carriage and resistance of Streptococcus prieumarriae. Clirr. Infect. Dis. (1998) 26:248–249.
   PubMedGoogle Scholar
• CHERN KC, SHRESTHA SK, CEVALLOS V etal.: Alterations in the conjunctival bacterial flora following a single dose of azithromycin in a trachoma endemic area. Br I Ophthalmal. (1999) 83:1332–1335.
   Google Scholar
• BAILEY R, LIETMAN T: The SAFE strategy for the elimination of trachoma by (2020): will it work? Bull. World Health Org. (2001) 78(3):233–236.
   Google Scholar
• BAILEY R, OSMOND C, MABEY DC, WHITTLE HC, WARD ME: Analysis of the household distribution of trachoma in a Gambian village using a Monte Carlo simulation procedure. Int. I Epidermal (1989) 18:944–951.
   PubMed Web of Science ®Google Scholar
• HOLM SO, JHA HC, BHATTA RC etal.:Comparison of two azithromycin distribution strategies for controlling trachoma in Nepal. Bull. World Health Org. (2001) 79:194–200.
   Google Scholar
• FRICK KD, LIETMAN TM, HOLM SO, JHA HC, CHAUDHARY JSP, BHATTA RC: Cost-effectiveness of trachoma control measure: comparing targeted household treatment and mass treatment of children. Bull. World Health Org. (2001) 79(3):201–207.
   PubMedGoogle Scholar
• SOLOMON AW, AKUDIBILLAH J, ABUGRI P eta].: Pilot study of the use of community volunteers to distribute azithromycin for trachoma control in Ghana. Bull. World Health Org. (2001) 79(1):8–14.
   Google Scholar
• LIETMAN T, PORCO T, DAWSON C, BLOWER S: Global elimination of trachoma: how frequently should we administer mass chemotherapy? Nat. Med. (1999) 5:572-576. •Mathematical model of mass treatment with azithromycin.
   Google Scholar
• EMERSON PM, CAIRNCROSS S, BAILEY RL, MABEY DC: Review of the evidence base for the 'F and E' components of the SAFE strategy for trachoma control. Trap. Med. Int. Health (2000) 5:515–527.
   PubMed Web of Science ®Google Scholar